Metformin Accord

Metformin, the active ingredient in Metformin Accord, is a Biguanide presented as an oral tablet for oral use. It lowers elevated blood glucose levels and is indicated for the management of type 2 diabetes mellitus in adult patients. It improves peripheral insulin sensitivity and reduces hepatic glucose production, helping to achieve glycaemic control.

GNH USA supplies Metformin Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company follows stringent quality standards and provides regulatory documentation to support import and distribution across multiple regions.

Metformin is used primarily in the management of disorders related to impaired glucose regulation.

- Type 2 diabetes mellitus: improves glycaemic control by lowering fasting and post‑prandial blood glucose. - Prediabetes: delays progression to overt diabetes by enhancing insulin sensitivity. - Polycystic ovary syndrome (off‑label): may improve ovulatory function and reduce androgen levels.

Metformin may be associated with a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Gastrointestinal upset: nausea, abdominal discomfort, and loss of appetite. - Diarrhea: frequent loose stools, especially during treatment initiation. - Metallic taste: transient alteration in taste perception. - Flatulence: increased intestinal gas. - Weight loss: modest reduction in body weight.

Serious or Rare Side Effects: - Lactic acidosis: life‑threatening accumulation of lactate, particularly in renal impairment. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatic failure: marked elevation of liver enzymes and liver dysfunction. - Vitamin B12 deficiency: long‑term use may reduce absorption leading to anemia. - Hypoglycaemia: rare when combined with other glucose‑lowering agents.

Before initiating Metformin, several safety considerations should be evaluated to minimise risk. - Renal function: assess creatinine clearance and avoid use in severe renal impairment. - Hepatic disease: contraindicated in patients with significant liver dysfunction. - Alcohol consumption: limit intake to reduce risk of lactic acidosis. - Cardiovascular surgery: withhold Metformin 48 hours before and after procedures involving contrast. - Elderly patients: monitor renal function and dosage closely due to increased susceptibility. - Store at ambient temperature: keep in original container, protect from moisture and heat.

Metformin can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Iodinated contrast agents: may precipitate acute renal failure; discontinue Metformin before imaging. - Cimetidine: can increase Metformin plasma concentrations, raising risk of toxicity. - Alcohol (excessive): potentiates risk of lactic acidosis.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask hypoglycaemia symptoms. - Diuretics (thiazides): can affect renal clearance of Metformin. - ACE inhibitors or ARBs: monitor renal function when combined. - Oral contraceptives: may modestly increase Metformin levels. - Rifampicin: may reduce Metformin exposure, requiring dose adjustment.